다발성 경화증 치료제 시장 : 규모, 점유율, 성장 : 유형별, 용도별, 지역별 인사이트 및 예측(2026-2034년)

Growth Factors of multiple sclerosis drugs Market

The global multiple sclerosis drugs market was valued at USD 21.07 billion in 2025 and is projected to grow to USD 22.95 billion in 2026, reaching USD 53.20 billion by 2034, registering a strong CAGR of 11.08% during the forecast period (2026-2034). The rapid growth reflects increasing disease prevalence, continuous innovation in drug development, and improved access to treatment globally.

North America dominated the market in 2025, accounting for a 48.51% share, supported by high healthcare spending, advanced research infrastructure, and strong awareness initiatives.

Market Overview

Multiple sclerosis (MS) is a chronic immune-mediated disease affecting the central nervous system, leading to inflammation, demyelination, and neurodegeneration. The global patient pool has increased significantly, rising from 2.3 million in 2013 to 2.8 million in 2020, which has intensified the demand for effective therapies.

The market is primarily driven by the rising need for disease-modifying therapies (DMTs), increasing diagnosis rates, and expanding treatment accessibility. Governments and healthcare organizations are actively supporting awareness and funding research, contributing to sustained market expansion.

Market Trends

Rising Adoption of Monoclonal Antibodies

A key trend shaping the market is the increasing use of monoclonal antibodies for MS treatment. These therapies offer targeted mechanisms, improved efficacy, and reduced relapse rates. Drugs such as Ocrevus have gained significant traction, contributing to strong revenue growth.

Pharmaceutical companies are focusing on developing advanced biologics and antibody-based therapies, which are expected to redefine treatment protocols and improve patient outcomes over the forecast period.

Market Growth Drivers

Increasing R&D Investments

The growing emphasis on research and development is a major driver of market growth. Leading pharmaceutical companies are investing heavily in clinical trials and pipeline development to introduce innovative therapies with better safety and efficacy profiles.

Several drugs under development target different mechanisms of action, which could significantly transform MS treatment strategies in the coming years.

Government Support and Awareness Programs

Government initiatives and awareness campaigns are playing a vital role in market expansion. Programs such as Multiple Sclerosis Awareness Month and funding by organizations like the National MS Society are improving early diagnosis and treatment adoption.

Favorable reimbursement policies in developed regions further support patient access to high-cost therapies, boosting overall market growth.

Restraining Factors

High Cost of Treatment

Despite advancements, the high cost of MS drugs remains a significant challenge. Disease-modifying therapies can cost up to USD 94,000 annually, limiting accessibility, especially in low- and middle-income countries.

Rising out-of-pocket expenses and insurance restrictions can lead to reduced treatment adherence, negatively impacting market growth.

Market Segmentation Analysis

By Drug Class

The market is segmented into immunomodulators, immunosuppressants, interferons, and others.

• Immunomodulators dominate due to high efficacy and continuous product launches.
• The "others" segment, including monoclonal antibodies, held a significant share (47.63% in 2026) due to their effectiveness in reducing relapses.

By Route of Administration

• The injection segment dominated with a 57.96% share in 2026, driven by increasing approvals of injectable therapies.
• The oral segment is expected to grow at the fastest rate due to convenience and rising product launches.

By Distribution Channel

Hospital pharmacies led the market with a 48.94% share in 2026, supported by reimbursement policies and advanced treatment availability. Online pharmacies are witnessing rapid growth due to increasing digital adoption and home delivery trends.

Regional Insights

• North America: Valued at USD 10.22 billion in 2025, driven by strong R&D and awareness initiatives.
• Europe: Accounted for USD 5.93 billion in 2025, supported by reimbursement policies and rising prevalence.
• Asia Pacific: Reached USD 2.77 billion in 2025, with growth fueled by improving healthcare infrastructure and partnerships.
• Latin America and Middle East & Africa: Emerging regions showing steady growth due to increasing healthcare investments.

Key Companies

The market is highly competitive, with major players focusing on innovation and portfolio expansion. Leading companies include:

• Biogen
• Pfizer Inc.
• F. Hoffmann-La Roche Ltd.
• Novartis AG
• Sanofi
• Merck & Co., Inc.

These companies are actively engaged in collaborations, acquisitions, and product launches to strengthen their market position.

Industry Developments

Recent developments include:

• FDA approval of biosimilar drug Tyruko (2023)
• Strategic collaborations between major pharmaceutical firms
• Launch of new oral and injectable therapies
• Expansion of clinical pipelines targeting innovative treatment mechanisms

Conclusion

The multiple sclerosis drugs market is poised for robust growth, expanding from USD 21.07 billion in 2025 to USD 53.20 billion by 2034. This growth is driven by increasing disease prevalence, strong R&D investments, and advancements in biologics such as monoclonal antibodies. While high treatment costs remain a key challenge, supportive government initiatives, improved awareness, and continuous innovation are expected to enhance accessibility and treatment outcomes. Overall, the market presents significant opportunities for pharmaceutical companies to develop cost-effective and advanced therapies, ensuring sustained growth during the forecast period.

Segmentation By Drug Class

• Immunomodulators
• Immunosuppressants
• Interferons
• Others

By Route of Administration

• Oral
• Injection
  • Intramuscular
  • Subcutaneous
  • Intravenous

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

By Geography

• North America (By Drug Class, by Route of Administration, by Distribution Channel, and by Country)
  • U.S.
  • Canada
• Europe (By Drug Class, Route of Administration, Distribution Channel, and Country/Sub-region)
  • U.K.
  • Germany
  • France
  • Italy
  • Spain
  • Scandinavia
  • Rest of Europe
• Asia Pacific (By Drug Class, Route of Administration, Distribution Channel, and Country/Sub-region)
  • Japan
  • China
  • India
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America (By Drug Class, Route of Administration, Distribution Channel, and Country/Sub-region)
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa (By Drug Class, Route of Administration, Distribution Channel, and Country/Sub-region)
  • South Africa
  • GCC
  • Rest of the Middle East & Africa

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Prevalence of Multiple Sclerosis - For Key Countries/Regions, 2025/2025
• 4.2. Regulatory Scenario - For Key Countries/Regions
• 4.3. Patent Snapshot, By Key Players
• 4.4. Pipeline Analysis & R&D Investments
• 4.5. New Product Launches, By Key Players
• 4.6. Key Industry Developments - Mergers, Acquisitions and Partnerships
• 4.7. Overview: Multiple Sclerosis Treatment Cost
• 4.8. Impact of COVID-19 on the Market

5. Global Multiple Sclerosis Drugs Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Drug Class
  • 5.1.1. Immunomodulators
  • 5.1.2. Immunosuppressants
  • 5.1.3. Interferons
  • 5.1.4. Others
• 5.2. Market Analysis, Insights and Forecast - By Route of Administration
  • 5.2.1. Oral
  • 5.2.2. Injection
    • 5.2.2.1. Intramuscular
    • 5.2.2.2. Subcutaneous
    • 5.2.2.3. Intravenous
• 5.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 5.3.1. Hospital Pharmacy
  • 5.3.2. Retail Pharmacy
  • 5.3.3. Online Pharmacy
• 5.4. Market Analysis, Insights and Forecast - By Region
  • 5.4.1. North America
  • 5.4.2. Europe
  • 5.4.3. Asia Pacific
  • 5.4.4. Latin America
  • 5.4.5. Middle East & Africa

6. North America Multiple Sclerosis Drugs Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Drug Class
  • 6.1.1. Immunomodulators
  • 6.1.2. Immunosuppressants
  • 6.1.3. Interferons
  • 6.1.4. Others
• 6.2. Market Analysis, Insights and Forecast - By Route of Administration
  • 6.2.1. Oral
  • 6.2.2. Injection
    • 6.2.2.1. Intramuscular
    • 6.2.2.2. Subcutaneous
    • 6.2.2.3. Intravenous
• 6.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 6.3.1. Hospital Pharmacy
  • 6.3.2. Retail Pharmacy
  • 6.3.3. Online Pharmacy
• 6.4. Market Analysis, Insights and Forecast - By Country
  • 6.4.1. U.S.
  • 6.4.2. Canada

7. Europe Multiple Sclerosis Drugs Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Drug Class
  • 7.1.1. Immunomodulators
  • 7.1.2. Immunosuppressants
  • 7.1.3. Interferons
  • 7.1.4. Others
• 7.2. Market Analysis, Insights and Forecast - By Route of Administration
  • 7.2.1. Oral
  • 7.2.2. Injection
    • 7.2.2.1. Intramuscular
    • 7.2.2.2. Subcutaneous
    • 7.2.2.3. Intravenous
• 7.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 7.3.1. Hospital Pharmacy
  • 7.3.2. Retail Pharmacy
  • 7.3.3. Online Pharmacy
• 7.4. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 7.4.1. Germany
  • 7.4.2. U.K.
  • 7.4.3. France
  • 7.4.4. Italy
  • 7.4.5. Spain
  • 7.4.6. Scandinavia
  • 7.4.7. Rest of Europe

8. Asia Pacific Multiple Sclerosis Drugs Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Drug Class
  • 8.1.1. Immunomodulators
  • 8.1.2. Immunosuppressants
  • 8.1.3. Interferons
  • 8.1.4. Others
• 8.2. Market Analysis, Insights and Forecast - By Route of Administration
  • 8.2.1. Oral
  • 8.2.2. Injection
    • 8.2.2.1. Intramuscular
    • 8.2.2.2. Subcutaneous
    • 8.2.2.3. Intravenous
• 8.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 8.3.1. Hospital Pharmacy
  • 8.3.2. Retail Pharmacy
  • 8.3.3. Online Pharmacy
• 8.4. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 8.4.1. China
  • 8.4.2. India
  • 8.4.3. Japan
  • 8.4.4. Australia
  • 8.4.5. Southeast Asia
  • 8.4.6. Rest of Asia Pacific

9. Latin America Multiple Sclerosis Drugs Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Drug Class
  • 9.1.1. Immunomodulators
  • 9.1.2. Immunosuppressants
  • 9.1.3. Interferons
  • 9.1.4. Others
• 9.2. Market Analysis, Insights and Forecast - By Route of Administration
  • 9.2.1. Oral
  • 9.2.2. Injection
    • 9.2.2.1. Intramuscular
    • 9.2.2.2. Subcutaneous
    • 9.2.2.3. Intravenous
• 9.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 9.3.1. Hospital Pharmacy
  • 9.3.2. Retail Pharmacy
  • 9.3.3. Online Pharmacy
• 9.4. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 9.4.1. Brazil
  • 9.4.2. Mexico
  • 9.4.3. Rest of Latin America

10. Middle East & Africa Multiple Sclerosis Drugs Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Drug Class
  • 10.1.1. Immunomodulators
  • 10.1.2. Immunosuppressants
  • 10.1.3. Interferons
  • 10.1.4. Others
• 10.2. Market Analysis, Insights and Forecast - By Route of Administration
  • 10.2.1. Oral
  • 10.2.2. Injection
    • 10.2.2.1. Intramuscular
    • 10.2.2.2. Subcutaneous
    • 10.2.2.3. Intravenous
• 10.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 10.3.1. Hospital Pharmacy
  • 10.3.2. Retail Pharmacy
  • 10.3.3. Online Pharmacy
• 10.4. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 10.4.1. South Africa
  • 10.4.2. GCC
  • 10.4.3. Rest of Middle East & Africa

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2025)
• 11.2. Company Profiles
  • 11.2.1. Biogen
    • 11.2.1.1. Overview
    • 11.2.1.2. Products & Services
    • 11.2.1.3. SWOT Analysis
    • 11.2.1.4. Recent Developments
    • 11.2.1.5. Strategies
    • 11.2.1.6. Financials (Based on Availability)
  • 11.2.2. Teva Pharmaceutical Industries Ltd.
    • 11.2.2.1. Overview
    • 11.2.2.2. Products & Services
    • 11.2.2.3. SWOT Analysis
    • 11.2.2.4. Recent Developments
    • 11.2.2.5. Strategies
    • 11.2.2.6. Financials (Based on Availability)
  • 11.2.3. Merck KGaA
    • 11.2.3.1. Overview
    • 11.2.3.2. Products & Services
    • 11.2.3.3. SWOT Analysis
    • 11.2.3.4. Recent Developments
    • 11.2.3.5. Strategies
    • 11.2.3.6. Financials (Based on Availability)
  • 11.2.4. Sanofi
    • 11.2.4.1. Overview
    • 11.2.4.2. Products & Services
    • 11.2.4.3. SWOT Analysis
    • 11.2.4.4. Recent Developments
    • 11.2.4.5. Strategies
    • 11.2.4.6. Financials (Based on Availability)
  • 11.2.5. Novartis AG
    • 11.2.5.1. Overview
    • 11.2.5.2. Products & Services
    • 11.2.5.3. SWOT Analysis
    • 11.2.5.4. Recent Developments
    • 11.2.5.5. Strategies
    • 11.2.5.6. Financials (Based on Availability)
  • 11.2.6. F. Hoffmann-La Roche Ltd.
    • 11.2.6.1. Overview
    • 11.2.6.2. Products & Services
    • 11.2.6.3. SWOT Analysis
    • 11.2.6.4. Recent Developments
    • 11.2.6.5. Strategies
    • 11.2.6.6. Financials (Based on Availability)
  • 11.2.7. Pfizer Inc.
    • 11.2.7.1. Overview
    • 11.2.7.2. Products & Services
    • 11.2.7.3. SWOT Analysis
    • 11.2.7.4. Recent Developments
    • 11.2.7.5. Strategies
    • 11.2.7.6. Financials (Based on Availability)
  • 11.2.8. Janssen Pharmaceuticals, Inc. (Johnson & Johnson Corporation)
    • 11.2.8.1. Overview
    • 11.2.8.2. Products & Services
    • 11.2.8.3. SWOT Analysis
    • 11.2.8.4. Recent Developments
    • 11.2.8.5. Strategies
    • 11.2.8.6. Financials (Based on Availability)
  • 11.2.9. Bristol-Myers Squibb Company
    • 11.2.9.1. Overview
    • 11.2.9.2. Products & Services
    • 11.2.9.3. SWOT Analysis
    • 11.2.9.4. Recent Developments
    • 11.2.9.5. Strategies
    • 11.2.9.6. Financials (Based on Availability)